The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder due to mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular surface defects that lead to the loss of vision.
Currently no specific treatments for this pathology exist leaving patients with supportive care to alleviate symptoms and thus greatly reduced quality of life.
We have identified a novel therapeutic strategy to preserve patient’s – affected by EEC syndrome– vision. We have demonstrated that applying a proprietary siRNA contrasts untoward effects of a causal mutation in the p63 gene in the patient derived models of the disease.
This finding provides a basis for the development of a therapeutic strategy that targets the cause of the disease.


Lead Optimization/Preclinical



Download the brochure

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • Therapeutic factors for the treatment of PolyQ diseases

    The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list.[...]

  • Method of treatment for human cytomegalovirus associated infections

    Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that infects from 60% to nearly 80% of the human population worldwide and, although rarely, causes serious multi-organ infections, such as pneumonia, gastrointestinal diseases and retinitis, which can be fatal in immunosuppressed patients.[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation